Application of SPECT/PET to 70 patients with lymphoma: monitoring response to therapy.
- Author:
Hui YAO
1
;
Xi-Nan CEN
;
Ze-Yin LIANG
;
Jin-Ping OU
;
Zhi-Xiang QIU
;
Wen-Sheng WANG
;
Wei-Lin XU
;
Yuan LI
;
Yue YIN
;
Mang-Ju WANG
;
Yu-Jun DONG
;
Li-Hong WANG
;
Han-Yun REN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Fluorodeoxyglucose F18; Humans; Lymphoma; Prognosis; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Treatment Outcome
- From: Chinese Journal of Hematology 2010;31(10):667-670
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the image of SPECT/PET (18)F-FDG in monitoring response to therapy for lymphoma patients.
METHODSA retrospective study was performed in 83 SPECT/PET studies for 70 patients with lymphoma from 1998 to 2008 in our hospital. The risk factors for survival rate were analyzed by univariate analysis.
RESULTSForty patients received SPECT/PET after 2 - 4 cycles of chemotheraphy, the median PFS in patients with positive and negative group were 5.5 months and 15.5 months, 2-year PFS were 12.5% and 66.8%; the median OS were 12.5 months and 17 months, and 1-year OS were 28.8% and 94.1%, respectively, all being of significant difference between two groups (P = 0.003). Forty-three patients performed posttreatment SPECT/PET, the median PFS in patients with positive and negative group were 10 months and 23 months, the 2-year PFS were 23.3% and 83.2%; the median OS were 17 months and 27 months and the 2-year OS were 60.0% and 100% respectively, all being of significant difference (P = 0.001).
CONCLUSIONSPECT/PET has significant value in monitoring response to therapy and predicting prognosis for patients with lymphoma.
